Weight Loss of 10% Beneficial in Overweight, Not Obese, With DM

Share this content:
Weight Loss of 10% Beneficial in Overweight, Not Obese, With DM
Weight Loss of 10% Beneficial in Overweight, Not Obese, With DM

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- For overweight, but not obese, individuals with type 2 diabetes (T2D), sustained weight loss (WL) of 10 percent body weight is associated with clinically meaningful cardiometabolic changes, according to research published online Feb. 19 in Diabetes Care.

John M. Wentworth, M.B.B.S., Ph.D., from Monash University in Clayton, Australia, and colleagues reported five-year outcomes of a randomized trial of laparoscopic adjustable gastric band (GB) surgery in overweight, but not obese, Australians with T2D of less than five years' duration. Twenty-two participants were randomized to GB combined with medical care and 23 to medical care alone (MED).

The researchers found that over five years of the study, the average weight loss was 12.2 and 1.8 percent in GB and MED participants, respectively. Diabetes remission was seen in 23 and 9 percent of GB and MED participants, respectively, at five years. GB participants used fewer glucose-lowering medications and they had 10.4 mmol/mol lower hemoglobin A1c than MED participants over five years of follow-up. In the context of less frequent use of lipid-lowering drugs, the mean high-density lipoprotein cholesterol was 0.24 mmol/L higher and triglycerides 0.7 mmol/L lower in GB participants, while low-density lipoprotein cholesterol was 0.5 mmol/L higher. Quality of life and health utility showed early and sustained improvement in the GB group.

"Sustained WL of 10 percent body weight is a powerful therapy for overweight but not obese people with T2DM," the authors write.

A grant from Allergan was received by the Center for Obesity Research and Education at Monash University, which funded the study. Allergan also donated the lap-band prostheses used in the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »